EMD 640744

Drug Profile

EMD 640744

Alternative Names: DPX-Survivac; EMD-640744; Survivac

Latest Information Update: 19 Apr 2017

Price : $50

At a glance

  • Originator Merck Serono
  • Developer Immunovaccine; Merck Serono
  • Class Cancer vaccines; Peptide vaccines; Peptides
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Ovarian cancer
  • New Molecular Entity No

Highest Development Phases

  • Phase II Diffuse large B cell lymphoma
  • Phase I/II Fallopian tube cancer; Ovarian cancer; Peritoneal cancer; Solid tumours

Most Recent Events

  • 11 Apr 2017 Health Canada approves clinical trial application for EMD 640744 and Pembrolizumab in Ovarian cancer
  • 29 Mar 2017 First interim efficacy and adverse events data from a phase Ib trial in Ovarian cancer released by Immunovaccine
  • 20 Jan 2017 University Health Network, Toronto, Merck Sharp & Dohme Corp. and ImmunoVaccine Technologies plan a phase II trial for Ovarian cancer, Fallopian tube cancer and Peritoneal cancer (Combination therapy, Late-stage disease, Second-line therapy or greater) in Canada (NCT03029403)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top